Nasdaq · Biotech stocks database
RTSN — Retension Pharmaceuticals Inc.
RTSN (Retension Pharmaceuticals Inc.) stock: $11.48, $90.4M market cap, $52.6M cash, $37.8M EV, $113.8M fully diluted market cap. Next expected readout: Mar-27. Lead program: RTN-001 (Uncontrolled Hypertension), Phase 2. Data from Fully Diluted's biotech stocks database.
Balance sheet
| Cash | $52.6M |
|---|
| Debt | $0.0M |
|---|
| Net cash | $52.6M |
|---|
| Enterprise value | $37.8M |
|---|
| Basic shares | 8.3M shares |
|---|
| Fully diluted shares | 9.9M shares |
|---|
| Fully diluted market cap | $113.8M |
|---|
| Cash per share | $6.31 |
|---|
Share structure
Cap table as of 2026-10-13.
Price history
Loading RTSN daily closes…
Loading price history…
Asset data not yet available for this company.
Pipeline
| Lead drug | RTN-001 |
|---|
| Lead indication | Uncontrolled Hypertension |
|---|
| Lead phase | Phase 2 |
|---|
| Active trials | 1 |
|---|
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.